שווי הפעילות העסקית: sonnetbio.com (SONN)

Sonnet BioTherapeutics (SONN) relies on patent protection for unique protein modification methods, guaranteeing its leadership status in high-cost medical niches. The business focuses on R&D development and the creation of extended-release drug delivery systems for combating tumors. The current market quotes illustrated below, with an Enterprise Value of 8.67, confirm growth potential driven by successful clinical trials and future contracts with pharma behemoths.

Enterprise value determines the actual buyout price of a business, accounting for debt load and liquid assets. The formula sums market capitalization with liabilities, subtracting cash to identify the net financial leverage. The trend of total capitalization including debt reflects the company's sensitivity to market cycles. For Sonnet BioTherapeutics (SONN), this indicator is critical due to high R&D expenditures. Investments in the FHAB platform directly impact asset value.